Targeting ATP-citrate lyase across cardiometabolic and oncologic disease
Pharmacological Research · 2026
DOI: 10.1016/j.phrs.2026.108348 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2026. Verfasst von Chiara Macchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", Università degli Studi di Milano, Milan, Italy. Hauptthemen laut MEDLINE: ATP Citrate (pro-S)-Lyase, Neoplasms, Cardiovascular Diseases, Metabolic Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Ministero dell'Istruzione dell'Università e della Ricerca, Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
ATP-citrate lyase (ACLY) is a key metabolic enzyme that links mitochondrial citrate export to the generation of cytosolic acetyl-CoA, thereby supporting de novo lipogenesis, cholesterol biosynthesis, protein acetylation, chromatin remodelling, and transcriptional control. Interest in ACLY inhibition initially arose from its lipid-lowering properties and led to the clinical development of bempedoic acid, whose ability to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes now provides the strongest clinical proof of concept for targeting this pathway. Beyond dyslipidaemia, preclinical evidence suggests that targeting the ACLY pathway and related bempedoic acid-responsive metabolic programs may ameliorate metabolic dysfunction-associated steatotic liver disease (MASLD). ACLY inhibition is expected to reduce de novo fatty-acid and cholesterol synthesis by limiting cytosolic acetyl-CoA availability, whereas parent bempedoic acid can directly activate PPARα, and thereby enhance fatty-acid oxidation. However, unlike the cardiovascular setting, robust clinical data supporting ACLY inhibition in MASLD are still lacking. More recently, the identification of nuclear ACLY functions has substantially expanded its biological significance, establishing ACLY as a metabolic-epigenetic integrator that couples nutrient availability to chromatin remodelling, transcriptional programs and immune responses. In cancer, dysregulated ACLY activity contributes to tumour growth, metabolic plasticity, therapy resistance and immune evasion, and its inhibition has shown promising antitumour effects in preclinical models. This review summarizes ACLY biology and pharmacology, emphasizing established cardiovascular applications, emerging MASLD opportunities and exploratory oncologic indications, while highlighting unresolved translational questions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", Università degli Studi di Milano, Milan, Italy.
- Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", Università degli Studi di Milano, Milan, Italy; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
- Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", Università degli Studi di Milano, Milan, Italy; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy. Electr…
- Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", Università degli Studi di Milano, Milan, Italy; Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore…
Förderung
- Ministry of Health
- Ministero dell'Istruzione dell'Università e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro
- European Commission Marie Sklodowska-Curie Actions
Zitieren
APA
Macchi, C., Pedretti, S., Ghisletti, S., Corsini, A., Mitro, N., Sirtori, C. R., & Ruscica, M. (2026). Targeting ATP-citrate lyase across cardiometabolic and oncologic disease. Pharmacological Research. https://doi.org/10.1016/j.phrs.2026.108348
Vancouver
Macchi C, Pedretti S, Ghisletti S, Corsini A, Mitro N, Sirtori CR, et al. Targeting ATP-citrate lyase across cardiometabolic and oncologic disease. Pharmacological Research. 2026. doi:10.1016/j.phrs.2026.108348
BibTeX
@article{Macchi2026,
author = {Macchi, Chiara and Pedretti, Silvia and Ghisletti, Serena and Corsini, Alberto and Mitro, Nico and Sirtori, Cesare R and Ruscica, Massimiliano},
title = {Targeting ATP-citrate lyase across cardiometabolic and oncologic disease},
journal = {Pharmacological Research},
year = {2026},
doi = {10.1016/j.phrs.2026.108348}
}
EUVIMED